Stephen Sabba
Net worth: 8 M $ as of 30/05/2026
Net worth: 8 M $ as of 30/05/2026
Dr. Stephen L.
Sabba, MD, is an Independent Director at Ligand Pharmaceuticals, Inc., an Analyst & Fund Manager at Knott Partners LP and a Principal at Dorset Management Corp.
He is on the Board of Directors at Ligand Pharmaceuticals, Inc.
Dr. Sabba was previously employed as an Independent Director by QLT, Inc., an Independent Director by Novelion Therapeutics, Inc., a Member by Kilkenny Capital Management LLC, a Director-Research by Kilkenny Capital Management LLC, and a Research Director by Sturza Institutional Research.
He received his undergraduate degree from Cornell University and a doctorate degree from New York University School of Medicine.
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
| 15/06/2026 | 33,629 ( 0.17% ) | 8 M $ | 30/05/2026 |
| Companies | Position | Start |
|---|---|---|
| LIGAND PHARMACEUTICALS INCORPORATED | Director/Board Member | 03/08/2008 |
Knott Partners LP
Knott Partners LP Investment ManagersFinance Knott Partners specializes in pairing value-oriented stock purchases with short sales. | Analyst-Equity | 31/10/2006 |
Dorset Management Corp.
Dorset Management Corp. Investment ManagersFinance Provides investment advice | Corporate Officer/Principal | 31/10/2006 |
| Companies | Position | End |
|---|---|---|
| NOVELION THERAPEUTICS INC. | Director/Board Member | 15/01/2020 |
Kilkenny Capital Management LLC
Kilkenny Capital Management LLC Investment ManagersFinance Kilkenny Capital Management takes long positions in undervalued US small/mid-cap biotechnology companies and short positions in overvalued stocks in the same sector. The firm maintains a very high turnover rate | Director of Research - Equity | - |
Kilkenny Capital Management LLC
Kilkenny Capital Management LLC Investment ManagersFinance Kilkenny Capital Management takes long positions in undervalued US small/mid-cap biotechnology companies and short positions in overvalued stocks in the same sector. The firm maintains a very high turnover rate | Chief Tech/Sci/R&D Officer | 31/12/2005 |
QLT, Inc.
QLT, Inc. Miscellaneous Commercial ServicesCommercial Services Develops and markets ocular products | Director/Board Member | - |
Sturzas Institutional Research, Inc.
Sturzas Institutional Research, Inc. Investment Banks/BrokersFinance Provides investment research | Chief Tech/Sci/R&D Officer | - |
Active
Inactive
Listed companies
Private companies
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
| Private companies | 9 |
|---|---|
Ligand Pharmaceuticals, Inc.
Ligand Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company which develops and sells drug development technologies | Health Technology |
QLT, Inc.
QLT, Inc. Miscellaneous Commercial ServicesCommercial Services Develops and markets ocular products | Commercial Services |
Kilkenny Capital Management LLC
Kilkenny Capital Management LLC Investment ManagersFinance Kilkenny Capital Management takes long positions in undervalued US small/mid-cap biotechnology companies and short positions in overvalued stocks in the same sector. The firm maintains a very high turnover rate | Finance |
Dorset Management Corp.
Dorset Management Corp. Investment ManagersFinance Provides investment advice | Finance |
Cornell University
Cornell University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Sturzas Institutional Research, Inc.
Sturzas Institutional Research, Inc. Investment Banks/BrokersFinance Provides investment research | Finance |
Knott Partners LP
Knott Partners LP Investment ManagersFinance Knott Partners specializes in pairing value-oriented stock purchases with short sales. | Finance |
New York University School of Medicine
New York University School of Medicine Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Novelion Therapeutics, Inc.
Novelion Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops, manufactures and markets rare disease products, metreleptin and lomitapide | Health Technology |
Select your edition
All financial news and data tailored to specific country editions